Robert Lustig, MD: Reactive Oxygen Species (ROS) & Brain Disease Dementia, Autism Explained

Emery Pharma

Emery Pharma

9,717 views

Dr. Ron Najafi, CEO of Emery Pharma, introduces renowned pediatric endocrinologist Robert H. Lustig from UCSF, as he explores a compelling and controversial topic: the role of reactive oxygen species (ROS) and oxidative stress as a potential common pathway in neurodegenerative diseases like dementia and neurodevelopmental conditions such as autism.

In this thought-provoking presentation, Dr. Lustig discusses how mitochondrial dysfunction, metabolic stress, and environmental factors may contribute to excess ROS production—impacting brain health, aging, and disease progression. He connects cutting-edge research in metabolism, inflammation, and cellular damage to broader clinical implications for prevention and treatment.

This session is especially relevant for scientists, clinicians, and biotech professionals interested in:

Oxidative stress and mitochondrial biology
Neurodegeneration (Alzheimer’s, dementia)
Autism spectrum disorders
Metabolic disease and brain health
Translational medicine and emerging therapeutic strategies

🔬 Hosted by Emery Pharma, a leader in GLP / non-GLP bioanalysis, mass spectrometry, GMP-NMR and pharmaceutical research, this discussion bridges basic science with real-world clinical insights.

Keywords:
#ReactiveOxygenSpecies,  #oxidativestress  #stress  #dementia #dementiaprevention  #alzheimer  #disease  #autism  #mitochondrialhealth #mitochondrialfunction, #RobertLustig #UCSF  brain health, #metabolism  #inflammation  #neurodegeneration  #emerypharma  Ron Najafi, #bioanalyticalCRO , pharmaceutical research, translational medicine

About Emery Pharma:
Emery Pharma is deeply committed to advancing public health and exclusively focuses on projects that enhance the well-being of both individuals and the environment. As a comprehensive contract research laboratory, Emery Pharma provides extensive support across the entire spectrum of pharmaceutical development, covering small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more.

Emery Pharma's array of premium services includes analytical and bioanalytical solutions, microbiology and cell biology services, drug and impurity characterization, and comprehensive R&D with cGMP/GLP support. The Emery Pharma team excels in customizing innovative solutions tailored to the unique requirements of each client. They seamlessly oversee the entire process, from initial drug discovery to thorough data analysis and insights generation. Their expertise allows them to tackle scientific challenges proactively, ensuring clients avoid unnecessary setbacks.

Emery Pharma's accomplished chemists and biologists harness state-of-the-art technology, encompassing cutting-edge tools such as high-resolution mass spectrometry (Orbitrap), triple quad LC-MS/MS, GC-MS, preparative HPLC, and 400 MHz multinuclear NMR.

For further details, please don't hesitate to reach out to Emery Pharma at info@emerypharma.com or explore their website at:
https://emerypharma.com/